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Fibroblastic growth factor 23 (FGF23) is a bone-derived
hormone that has a pivotal role in the pathogenesis of
mineral disorders in chronic kidney disease. To study the
effect of parathyroid hormone (PTH) on FGF23, rats were
parathyroidectomized for a week and then implanted with
constant-delivery infusion pumps to provide vehicle, a
physiological, or a threefold supraphysiological dose of
parathyroid hormone. Parathyroidectomy resulted in a
significant decrease in blood ionized calcium, FGF23,
and calcitriol along with an increase in phosphorus
concentrations. PTH replacement produced a
dose-dependent increase in ionized calcium and FGF23
with decreased phosphorus. Calcitriol was also increased but
there was no dose effect of PTH treatment. To maintain
normal plasma calcitriol levels, two additional groups of
parathyroidectomized rats were given calcitriol and
temporarily treated with vehicle or the supraphysiological
dose of PTH. FGF23 was significantly increased by calcitriol in
the vehicle-treated rats but was not further increased above
that in rats given the supraphysiological dose of PTH in the
absence of calcitriol. Klotho expression in the kidney
decreased after parathyroidectomy but was restored by
hormone supplementation. Hence, our results show a direct
and an indirect effect of PTH on FGF23 secretion, the latter
through changes in calcitriol concentrations.
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Fibroblastic growth factor 23 (FGF23) is a bone-derived
hormone that plays an important function in regulating
mineral metabolism.1–4 Moreover, a growing body of evi-
dence for the pivotal role of FGF23 in the pathogenesis of
mineral disorders associated with chronic kidney disease is
being reported.5–9
Patients with chronic renal failure develop secondary
hyperparathyroidism. This is a consequence of phosphorus
retention, decline in serum calcium levels, and decreased
calcitriol production. To compensate these abnormalities,
parathyroid hormone (PTH) synthesis and secretion increase
and results in bone disorders.10,11
FGF23 is a phosphaturic hormone secreted by osteocytes
and osteoblasts in response to an increase in phosphorus load
and high calcitriol levels. FGF23 binds to the FGF23 receptor
(FGFR) and its co-receptor Klotho and causes both an
increase in urinary phosphorus excretion and a reduction in
calcitriol synthesis.12–14 As shown by recent publications,15,16
Klotho is necessary for FGF23 biological effect, as mice
overexpressing FGF23 with Klotho ablation are phenotypi-
cally similar to Klotho-deficient mice. In addition to the
kidney, the parathyroid glands also express FGFR and Klotho
and thus respond to FGF23 by decreasing PTH secretion.17–19
The reduction in PTH levels caused by FGF23 should lead
to a decrease in calcium and calcitriol concentrations and an
increase in phosphate. In fact, the decrease in calcium due to
the lack of PTH is reinforced by the low calcitriol and the
high phosphate. Thus, when FGF23 is persistently elevated,
there should be a mechanism to protect against hypocalce-
mia, which likely involves an inhibition in FGF23 secretion.
The decrease in calcitriol induced by low PTH actually
inhibits FGF23 production but, on the other hand, the
increase in phosphate that follows low PTH levels tends to
stimulate FGF23 synthesis. PTH might be necessary for
FGF23 secretion and thus low PTH would result in decreased
FGF23 levels. This would also help to explain the contra-
dictory action of FGF23 on plasma phosphorus—FGF23
directly decreases plasma phosphate, whereas it indirectly,
through decreased PTH levels, facilitates an increase in
plasma phosphate. Again, a possible explanation to this
paradox would be that PTH and FGF23 may be able to
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regulate each other. Finally, as there is a two-way regu-
lation between FGF23 and phosphate and between FGF23
and calcitriol, intuitively it would seem reasonable to expect
the same kind of regulation between FGF23 and PTH.
Thus, we hypothesized that, in addition to plasma
phosphorus and calcitriol, FGF23 secretion is also regulated
by PTH. The results of this study clearly show a stimulatory
effect of PTH on FGF23 secretion in an in vivo model of
parathyroidectomized rats.
RESULTS
Blood ionized calcium values remained at a physiological
level in sham-operated rats (range 1.17–1.23 mmol/l). Para-
thyroidectomized rats without PTH supplementation showed
a significant decrease in ionized calcium to values of 0.59±
0.08 mmol/l at day 10. Ionized calcium remained stabilized at
this lower level throughout the experiments in PTX0 rats
(0.56±0.12 and 0.60±0.7 mmol/l at days 20 and 28, respec-
tively). Parathyroidectomized rats that received a physio-
logical dose of PTH (PTX1) maintained ionized calcium
levels at similar values to those of the sham-operated animals
throughout the experiments (range 1.15–1.20 mmol/l). The
rats that received a supraphysiological dose of PTH had
elevated calcium values, which were significantly higher than
in the sham and PTX1 rats (1.60±0.21, 1.51±0.13,
and 1.46±0.18 mmol/l at days 10, 20, and 28, respectively;
Figure 1).
Plasma phosphorus significantly increased after parathyr-
oidectomy (from 6.3±1.3 to 11.1±1.3 mg/dl, at day 10) and
remained elevated at levels that almost doubled the values of
the sham-operated rats (10.9±1.6 and 11.6±3.4 mg/dl at
days 20 and 28, respectively). As with calcium, physiological
supplementation of PTH brought plasma phosphate back to
normal levels (range 5.3–6.5 mg/dl). Supraphysiological
administration of PTH resulted in a decrease in plasma
phosphate (5.3±1.4 mg/dl at day 10 and 4.5±0.9 mg/dl
at day 20). Plasma phosphate was significantly decreased at
day 28 (3.7±1.7 mg/dl, Po0.05 when compared with sham-
operated rats; Figure 2).
Calcitriol levels in plasma are depicted in Figure 3.
Sham-operated rats had mean calcitriol values in a range
between 99 and 130 pg/ml and no significant differences
were detected between sampling times. Parathyroidectomy
reduced calcitriol levels and the differences were significant
(Po0.05 vs sham) at days 10 (40±13 pg/ml) and 20 (52.1±
12.7 pg/ml). PTH supplementation restored calcitriol levels
to values that were not different from the sham-operated rats.
No significant differences in calcitriol were detected between
the PTX1 and PTX3 groups.
Mean plasma FGF23 concentration in sham-operated rats
was 170±17 pg/ml at day 10 and remained constant
throughout the experiments (175±25 and 219±20 pg/ml,
at days 20 and 28). After parathyroidectomy, a significant
decline in FGF23 values was observed at all sampling times
(range 70–100 pg/ml). Physiological PTH supplementation
restored FGF23 concentration to values that were not
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Figure 1 |Blood ionized calcium levels in sham-operated rats
(sham) and parathyroidectomized (PTX) rats supplemented
with no PTH (PTX0), a physiological dose of PTH (PTX1), or a
supraphysiological dose of PTH (PTX3; see Materials and
Methods for details). Samples were obtained 10, 20, and 28 days
after implantation of the pump for continuous parathyroid
hormone (PTH) administration. aPo0.05 vs sham, bPo0.05 vs
PTX0.
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Figure 2 |Plasma phosphate levels in sham-operated rats
(sham) and parathyroidectomized (PTX) rats supplemented
with no PTH (PTX0), a physiological dose of PTH (PTX1), or a
supraphysiological dose of PTH (PTX3; see Materials and
Methods for details). Samples were obtained 10, 20, and 28 days
after implantation of the pump for continuous parathyroid
hormone (PTH) administration. aPo0.05 vs sham, bPo0.05 vs
PTX0.
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Figure 3 |Plasma calcitriol levels in sham-operated rats (sham)
and parathyroidectomized (PTX) rats supplemented with no
PTH (PTX0), a physiological dose of PTH (PTX1), or a
supraphysiological dose of PTH (PTX3; see Materials and
Methods for details). Samples were obtained 10, 20, and 28 days
after implantation of the pump for continuous parathyroid
hormone (PTH) administration. aPo0.05 vs sham, bPo0.05 vs
PTX0.
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different from sham-operated animals (182–238 pg/ml). A
dose-dependent increase in FGF23 was observed with PTH
supplementation, as rats that received excess PTH also had
increased FGF23 values (363–425 pg/ml) that were signifi-
cantly different from sham and PTX1 groups (Figure 4).
Urinary fractional excretion of calcium in sham-operated
rats was 0.80±0.17%. Parathyroidectomy (more than
1 month without PTH with ensuing hypocalcemia) resulted
in a nonsignificant increase in fractional excretion of calcium
(1.14±0.19%) that was not modified by PTH supplemen-
tation (1.02±0.7 and 1.13±0.15% at days 20 and 28,
respectively). Conversely, urinary fractional excretion of
phosphorus significantly decreased after parathyroidectomy
(from 19.3±4.0 to 13.3±1.4%, Po0.05) and was increased
after physiological (29.3±2.5%) and supraphysiological
(50.2±8.0%) PTH supplementation (Table 1).
Two additional groups were studied to better elucidate the
influence of PTH-induced changes in calcitriol on the results.
Supplementation with 1,25-dihydroxyvitamin D (80 ng/kg)
significantly increased calcitriol (111.6±17.1 pg/ml) in PTX0
rats to levels that were non-different from sham-operated
animals (128.0±19.2 pg/ml). A considerable increase in
FGF23 was also observed in these animals (200.4±37.8
pg/ml) that was statistically significant (P¼ 0.007) when
compared with the values obtained before vitamin D
administration (87.5±25.3 pg/ml; Figure 5a). As shown in
Figure 5b, administration of calcitriol to PTX rats that had
received supraphysiological PTH supplementation for a week
before pump withdrawal also restored calcitriol values to the
levels found when exposed to high PTH (298.1±12.5 vs
298.8±14.2 pg/ml, nonsignificant). However, in these rats
FGF23 did not change after administering calcitriol (174.9±
25.6 vs 184.2±34.8 pg/ml, nonsignificant). Thus, FGF23 was
higher in the rats receiving PTH supplementation (383.4±
91.5 pg/ml) than after pump withdrawal (184.2±34.8 pg/ml,
Po0.05), although calcitriol values were similar in both
groups (298.1±12.5 vs 298.8±14.2 pg/ml, nonsignificant).
Plasma calcium and phosphate values of these additional
groups are shown in Table 1.
Figure 6 shows the results of Klotho and FGFR1
expression in the kidney. Klotho was clearly dependent on
PTH levels. Thus, decreased Klotho expression was observed
by western blot in PTX0 rats (74.4±5.5%, Po0.05) when
compared with sham-operated animals (100±0.1%), and
PTH supplementation significantly increased Klotho values
(118±3.3, Po0.01 vs PTH-deficient rats). These results were
also evident by immunohistochemistry. In contrast, no
changes in FGFR1 expression were apparent, either by
western blot or immunohistochemistry, in response to
changes in PTH.
DISCUSSION
This study was designed to investigate the role of PTH as a
regulatory factor of FGF23 in an in vivo model of
parathyroidectomized rats with and without PTH supple-
mentation. The results show that PTH is necessary to
maintain normal circulating FGF23 levels. In PTX rats, which
exhibit marked hyperphosphatemia, plasma FGF23 concen-
tration declines. Moreover, PTH supplementation increases
FGF23 concentrations in a dose-dependent manner, although
at the same time extracellular phosphorus declines. Changes
in calcitriol play a role in the stimulatory effect of PTH on
FGF23, but PTH can also modify FGF23 under conditions in
which calcitriol is controlled.
The PTX rat offers an excellent animal model to study the
biological effects of PTH suppression in vivo.20,21 In addition,
through controlled PTH administration using constant-rate
delivery pumps, PTH can be restored to normal levels and
even increased to supraphysiological concentrations. In this
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Figure 4 |Plasma fibroblastic growth factor 23 (FGF23) levels
in sham-operated rats (sham) and parathyroidectomized
(PTX) rats supplemented with no PTH (PTX0), a physiological
dose of PTH (PTX1), or a supraphysiological dose of PTH
(PTX3; see Materials and Methods for details). Samples were
obtained 10, 20, and 28 days after implantation of the pump for
continuous parathyroid hormone (PTH) administration. aPo0.05
vs sham, bPo0.05 vs PTX0, cPo0.05 vs PTX1.
Table 1 | Plasma ionized Ca2+ and P, and FECa and FEP in the
study groups
Treatment Ca2+ (mmol/l) P (mg/dl) FECa (%) FEP (%)
Group 1 (n=32)
Sham 1.23±0.05b 6.3±0.3b 0.80±0.17 19.3±4.0
PTX0 0.59±0.07a 11.6±0.9a 1.14±0.19 13.3±1.4
PTX1 1.18±0.09b 5.3±0.3b 1.02±0.17 29.3±2.5b
PTX3 1.46±0.18a,b 3.7±0.78b 1.13±0.15 50.2±8.0a,b
Group 2 (n=7)
Sham 1.18±0.02 6.3±0.5 — —
PTX0 0.55±0.04a 9.9±0.4a — —
PTX0+CTR 0.96±0.05a,b 10.4±0.7a — —
Group 3 (n=7)
PTX3 1.51±0.05 6.7±0.6 — —
PTX0-3PTH 0.93±0.07c 10.1±0.5c — —
PTX0-3PTH+CTR 0.94±0.05c 11.0±0.4c — —
Abbreviations: Ca2+, calcium; FECa, fractional excretion of calcium; FEP, fractional
excretion of phosphorus; P, phosphorus; PTH, parathyroid hormone; PTX,
parathyroidectomized.
Mean±s.e.
aPo0.05 vs sham, bPo0.05 vs PTX0, cPo0.05 vs PTX3.
Group 1=data obtained at the time of killing (28 days) in the main study. Group
2=additional group of parathyroidectomized rats that received calcitriol supple-
mentation. Group 3=additional group of parathyroidectomized rats that had been
exposed to supraphysiological levels of PTH and were administered calcitriol (see
Materials and Methods for details).
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model, the efficacy of the PTH manipulations is not
monitored through PTH measurements (as exogenous PTH
is not detected by the PTH assays) but rather by the changes
in plasma calcium. In the PTX rat plasma ionized calcium
declines by 50% at 1 week after the surgical procedure. In
addition, the definition of a physiological dose of PTH is
provided by a PTH infusion that can maintain ionized
calcium, phosphate, and calcitriol at normal levels in PTX
rats.22
In chronic kidney disease, there is a complex interaction
between phosphate, PTH, and FGF23. Phosphate retention
and the subsequent hyperphosphatemia are hallmarks in the
development of secondary hyperparathyroidism in dialysis
patients. Hyperphosphatemia stimulates PTH and FGF23
secretion.6,7 Both PTH and FGF23 have phosphaturic actions
that help to control phosphate. In addition to its renal
effects, PTH also promotes bone resorption and the calcium
extracted from bone exerts a negative feedback control on
PTH secretion. It is interesting to note that FGF23 directly
participates in this bone–parathyroid axis as FGF23 inhibits
PTH secretion.17–19 However, up to now, the influence
of PTH on FGF23 had not been documented. From a
physiological point of view, a regulatory effect of PTH
on FGF23 would make sense to balance the inhibition of
PTH by FGF23. Our results, demonstrating that PTH
stimulates FGF23 secretion, help to better delineate the
bone–parathyroid axis in which PTH affects the efflux of
calcium and FGF23 from bone and in turn both calcium and
FGF23 act as a negative feedback for PTH secretion.
FGF23 inhibits 1-a-hydroxylase activity in the kidney and
thus reduces calcitriol production.23,24 Conversely, PTH
stimulates 1-a-hydroxylase and increases calcitriol synth-
esis.25 Thus, PTX rats experience a reduction in calcitriol
levels that are restored by PTH supplementation. Conse-
quently, the effect of PTH on FGF23 could be mediated
through changes in calcitriol. The effect of vitamin D on
FGF23 has been studied in Klotho knockout mice. In these
knockouts, which exhibit low PTH and high phosphate
levels, FGF23 values are extremely high as a consequence of
increased vitamin D activity.26,27 Moreover, genetic deletion
of vitamin D 1-a-hydroxylase reduces FGF23 levels in this
animal model.28 Our results show some parallelism between
changes in FGF23 and calcitriol; however, it should also be
noted that: (1) at day 28, no significant changes in calcitriol
were detected but there were significant intergroup differ-
ences in FGF23, and (2) at all sampling times, rats receiving
supraphysiological PTH supplementation had normal calci-
triol values and elevated FGF23 concentrations. Thus, when
PTH is elevated, the effect of PTH on FGF23 seems to be
independent of changes in calcitriol. To better investigate the
hypothesis that the decrease in FGF23 associated with low
PTH could be mediated by reduced calcitriol levels, an
additional group of PTX rats that received calcitriol sup-
plements was studied. In these rats, calcitriol administration
restored physiological 1,25-dihydroxyvitamin D levels and
increased FGF23. Therefore, it seems that when PTH is low,
the increase in FGF23 that follows PTH supplementation is
mediated through changes in calcitriol. However, when
calcitriol was administered to PTX rats that had been
receiving PTH supplementation, the increase in calcitriol
was not accompanied by a concurrent increase in FGF23.
These results reinforce the notion that calcitriol plays a role in
the PTH effects on FGF23 when PTH is low. However, when
PTH is elevated, the effect on FGF23 is independent of
calcitriol.
Our results also demonstrate that in the absence of PTH,
hyperphosphatemia is not able to increase FGF23, as PTX
rats (which have no PTH and high phosphate) show a
decrease in FGF23 values. This is an interesting finding as
high phosphate can stimulate FGF23 even in cultured cells.29
It is likely that in our PTX rat model the absence of PTH
decreased the number or activity of cells involved in FGF23
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Figure 5 |Plasma fibroblastic growth factor 23 (FGF23) and
calcitriol (CTR) levels after calcitriol administration to
parathyroidectomized (PTX) rats. (a) Plasma FGF23 and
calcitriol concentrations in sham-operated rats (sham), and
parathyroidectomized rats that did not receive parathyroid
hormone (PTH) supplementation before (PTX0) and after
(PTX0þCTR) administering two doses of calcitriol (80 ng/kg
intraperitoneally (i.p.) every 24 h). aPo0.05 vs sham, bPo0.05 vs
PTX0. (b) Plasma FGF23 and calcitriol concentrations in
parathyroidectomized rats receiving supraphysiological PTH
supplementation (PTX3), in the same rats 24 h after withdrawal of
the pumps (PTX3-3PTH), and 12 h after receiving a single dose of
calcitriol (40 ng/kg i.p.; PTX3-3PTHþCTR). aPo0.05 vs PTX3,
bPo0.05 vs PTX3-3PTH.
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secretion. This contention is supported by reports demon-
strating that the activities of osteoblasts and/or osteocytes are
involved in the stimulation of FGF23 by PTH.30 Moreover, a
transient increase in FGF23 has been reported in thyroid
cancer patients who developed transient hypoparathyroidism
and hyperphosphatemia after surgery.31 Although these data
seem contradictory with the role of PTH as positive regulator
of FGF23 secretion, it should be noted that these patients had
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Figure 6 |Renal expression of Klotho and fibroblastic growth factor receptor 1 (FGFR1) in parathyroidectomized (PTX) rats.
(a) Western blot and immunochemistry of Klotho in renal tissue of sham-operated rats (sham), parathyroidectomized rats receiving no
parathyroid hormone (PTH) supplementation (PTX0), and parathyroidectomized rats receiving physiological PTH supplementation (PTX1).
aPo0.05 vs sham, bPo0.05 vs PTX0. (b) Western blot and immunochemistry of FGFR1 in renal tissue of sham-operated rats (sham),
parathyroidectomized rats receiving no PTH supplementation (PTX0), and parathyroidectomized rats receiving physiological PTH
supplementation (PTX1). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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quite high preoperatory PTH values. The elevated PTH
would have contributed to maintain an active population of
FGF23-secreting cells that, in turn, responded to post-
operative hyperphosphatemia.
Our results also show a lack of effect of FGF23 on urinary
regulation of phosphate in the absence of PTH. In PTX rats,
FGF23 levels were increased after calcitriol administration
but were not able to normalize their plasma phosphate. A
possible explanation for this finding could be the decreased
expression of Klotho in the kidneys of PTX rats found in the
present study. Conversely, PTH administration upregulated
Klotho, causing the renal tubuli to become responsive to
FGF23. These findings lead to the conclusion that in the
absence of PTH, decreased Klotho expression makes the renal
tubule refractory to increases in FGF23 that would typically
control hyperphosphatemia and highlight the importance of
PTH for renal phosphate excretion.
In conclusion, our results demonstrate that PTH is
necessary for FGF23 secretion. Actually, high phosphate does
not stimulate FGF23 when PTH is low, and hence in this
context PTH is likely to be more important than phosphate
in the regulation of FGF23 secretion. The decrease in
calcitriol that ensues parathyroidectomy plays an important
role in the inhibitory effect of low PTH on FGF23 produc-
tion. However, in rats with high PTH levels, the effect of PTH
on FGF23 seems to be independent of changes in calcitriol.
MATERIALS AND METHODS
Animals and surgical procedures
Male Wistar rats weighing 200 g (Animal Breeding Facility of the
University of Cordoba, Spain) were housed with a 12-h light/dark
cycle and given ad libitum access to standard diet (calcium¼ 0.6%,
phosphorus¼ 0.6%). All experimental protocols were reviewed and
approved by the ethics committee for animal research of the
University of Cordoba (Spain).
A selective parathyroidectomy (PTX) was performed as pre-
viously reported with the aid of a dissecting microscope.32 Briefly,
with the rat under general anesthesia (Sevofluorane; Abbott,
Madrid, Spain), the skin on the ventral part of the neck was
incised, the thyroid was exposed, and the parathyroid glands were
identified, dissected, and ablated. Hemorrhage was prevented by
electrocautery. Animals subjected to sham surgery underwent the
same procedure without parathyroid gland ablation.
At 1 week after PTX (day 0), blood was drawn to measure plasma
calcium levels. Parathyroidectomy was considered successful in rats
with ionized calcium levels o0.8 mmol/l. Subsequently, an Alzet
model 2ML4 osmotic minipump (Charles River Laboratories,
Barcelona, Spain) was implanted subcutaneously between the
shoulders. The osmotic pump was filled under aseptic conditions
with rat PTH (1–34 rat PTH, Sigma-Aldrich, St Louis, MO) diluted
in isosmotic saline with 2% cysteine (pH 1.4). The pump provided
continuous infusion and ensured a constant delivery of 2.5 ml/h for a
period of 28 days.
Experimental design
Animals (n¼ 32) were randomly allocated to four groups: sham
(n¼ 8) underwent a sham surgery and were not implanted pumps
for PTH infusion. A PTX group (PTX0, n¼ 8) did not receive PTH
supplementation, and were infused vehicle only (isosmotic saline
with 2% cysteine; Sigma-Aldrich). Two additional PTX groups
received either a physiological dose of PTH (0.022 mg per 100 g per
h; PTX1, n¼ 8), or three times the physiological dose of PTH
(0.066 mg per 100 g per h; PTX3, n¼ 8) through the infusion pump.
The physiological dose of PTH (0.022mg per 100 g per h) was
previously defined by its ability to maintain normal range of plasma
ionized calcium values (1.15–1.25 mmol/l) in PTX rats fed a 0.6%
calcium and 0.6% phosphorus diet.22
Blood was collected on days 10, 20, and 28 after pump
implantation (day 0). Blood (1 ml) was obtained by puncture of
the jugular vein with the rat under general anesthesia (Sevofluorane;
Abbott) on days 10 and 20. On day 28, blood was obtained during
killing by exanguination from the abdominal aorta. Urine was
collected on day 28 at the time of killing by direct punction of the
urinary bladder.
Two additional groups of parathyroidectomized rats received
calcitriol supplementation. In a group (n¼ 7), 1,25-dihydroxyvita-
min D was given to restore to normal the decreased calcitriol levels
induced by PTX. These PTX rats (same protocol as above) were
supplemented with 80 ng/kg intraperitoneal of calcitriol (Calcijex;
Abbott) for 2 consecutive days before killing (on day 10). Blood was
obtained 1 week after parathyroidectomy (day 0, PTX0) and the day
of killing (PTX0þCTR) for measurement of ionized calcium,
phosphate, FGF23, and calcitriol. In the second group, PTX rats
(n¼ 7) were implanted a PTH-delivery device and were infused
supraphysiological doses of PTH (0.066 mg per 100 g per h) for a
week. On day 8, the pumps were withdrawn and 24 h later a dose of
calcitriol (40 ng/kg) was administered. Blood was obtained for
measurement of biochemical parameters immediately before pump
withdrawal (PTX3), just before calcitriol administration (PTX3-3PTH),
and 12 h after administering calcitriol (PTX3-3PTHþCTR).
Blood and urine chemistries
Blood for measurements of ionized calcium levels was collected in
heparinized syringes and immediately analyzed using a Ciba-
Corning 634 ISE Ca2þ /pH Analyzer (Ciba-Corning, Essex, UK).
Afterward, plasma was separated by centrifugation and stored at
–20 1C until assayed. Plasma creatinine, phosphorus, and total
calcium were measured by spectrophotometry (Biosystems SA,
Barcelona, Spain). Plasma FGF23 levels were determined using a rat
FGF23 ELISA Kit (Kainos Laboratories, Tokyo, Japan). In plasma
samples, 1,25-dihydroxyvitamin D3 was measured using the RIA
assay (IDS kit, Boldon, UK).
Urine was obtained as described above for measurement of
urinary calcium and phosphorus excretion. The urinary concentra-
tion of calcium, phosphorus, and creatinine was measured by
spectrophotometry (Biosystems SA).
Molecular biology and immunohistochemistry
Protein extraction and western blot analysis. Proteins were
isolated from pieces of renal tissue by using a lysis buffer containing
HEPES (10 mmol/l), KCl (10 mmol/l), EDTA (0.1 mmol/l), EGTA
(0.1 mmol/l), DTT (1 mmol/L), PMSF (0.5 mmol/l), protease
inhibitor cocktail (70 mg/ml), and I-Gepal CA-630 (0.5%), pH 7.9
(Sigma-Aldrich). Protein concentration was determined by Bradford
method. For western blot analysis, 50 mg of protein was electro-
phoresed on a 7% sodium dodecyl sulfate-polyacrilamide gel
(Invitrogen, Carlsbad, CA) and electrophoretically transferred
(Transfer Systems, Bio-Rad, Hercules, CA) from the gels onto
nitrocellulose membranes (Invitrogen). The following steps were
performed with gentle shaking. Membranes were incubated in
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TTBS-L solution (20 mmol/l Tris-HCl (pH 7.6), 0.2% Tween 20,
150 mmol/l NaCl (Sigma-Aldrich), and 5% nonfat dry milk (Bio-
Rad)) at room temperature for 1 h to avoid nonspecific binding.
Membranes were then washed with TTBS buffer (the same
composition as TTBS-L without nonfat dry milk) and incubated
for 2 h at room temperature with a rabbit anti-FGFR1 antibody
(GeneTex, Irvine, CA; 1 mg/ml) or rabbit anti-klotho antibody
(Alpha Diagnostic, San Antonio, TX; 1 mg/ml). The membranes
were then washed with TTBS buffer and inmunolabeled using a
peroxidase-conjugated secondary antibody (1:5000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA). Finally, they were revealed on
autoradiographic film using ECL Plus Western Blotting Detection
System (GE Healthcare, Piscataway, NJ). Glyceraldehyde 3-phos-
phate dehydrogenase was used as housekeeping protein to ensure
equal loading of the gels. Protein levels were quantified using ImageJ
software (National Institutes of Health, Bethesda, MD).
Immunohistochemistry
Kidneys collected from rats were fixed in 4% formalin and
embedded in paraffin. Sections (3mm) were deparaffinized and
incubated in 0.3% H2O2 in methanol for 30 min. Next, sections were
microwave treated in 0.01 mmol/l citrate buffer (pH 6) for 20 min.
Sections were blocked with goat serum 10% for 40 min, then
sections were incubated overnight at 4 1C in a humidified chamber
with a rabbit anti-FGFR1 antibody (GeneTex; 1:500 dilution) or
rabbit anti-klotho antibody (Alpha Diagnostic; 1:100 dilution).
After rinsing, the sections were incubated for 40 min at room
temperature with peroxidase-labeled polymer conjugated to goat
anti-rabbit Igs and treated with 3,30 diaminobenzidine-tetrachloride
cromogen solution for 10 min (Envisionþ System HRP (DAB);
DakoCytomation, Glostrup, Denmark; 1:100 dilution). Every step
was followed by three washes with phosphate-buffered saline for
5 min. Sections were counterstained with hematoxylin (Dako).
Images of inmunolabeled sections were obtained using a photo-
microscope (Nikon Coolscope, Nikon Instruments, Melville, NY).
Statistics
Values are expressed as the mean±s.e. The difference between
means for two different groups was determined by t-test; the
difference between means for three or more groups was assessed by
analysis of variance. Fisher’s least significant difference test was used
as a post hoc procedure. Po0.05 was considered significant.
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